Literature DB >> 30415209

Constitutional mismatch repair deficiency as a differential diagnosis of neurofibromatosis type 1: consensus guidelines for testing a child without malignancy.

Manon Suerink1, Tim Ripperger2, Ludwine Messiaen3, Fred H Menko4, Franck Bourdeaut5, Chrystelle Colas6,7, Marjolijn Jongmans8,9, Yael Goldberg10, Maartje Nielsen1, Martine Muleris7, Mariëtte van Kouwen11, Irene Slavc12, Christian Kratz13, Hans F Vasen14, Laurence Brugiѐres15, Eric Legius16, Katharina Wimmer17.   

Abstract

Constitutional mismatch repair deficiency (CMMRD) is a rare childhood cancer predisposition syndrome caused by biallelic germline mutations in one of four mismatch-repair genes. Besides very high tumour risks, CMMRD phenotypes are often characterised by the presence of signs reminiscent of neurofibromatosis type 1 (NF1). Because NF1 signs may be present prior to tumour onset, CMMRD is a legitimate differential diagnosis in an otherwise healthy child suspected to have NF1/Legius syndrome without a detectable underlying NF1/SPRED1 germline mutation. However, no guidelines indicate when to counsel and test for CMMRD in this setting. Assuming that CMMRD is rare in these patients and that expected benefits of identifying CMMRD prior to tumour onset should outweigh potential harms associated with CMMRD counselling and testing in this setting, we aimed at elaborating a strategy to preselect, among children suspected to have NF1/Legius syndrome without a causative NF1/SPRED1 mutation and no overt malignancy, those children who have a higher probability of having CMMRD. At an interdisciplinary workshop, we discussed estimations of the frequency of CMMRD as a differential diagnosis of NF1 and potential benefits and harms of CMMRD counselling and testing in a healthy child with no malignancy. Preselection criteria and strategies for counselling and testing were developed and reviewed in two rounds of critical revisions. Existing diagnostic CMMRD criteria were adapted to serve as a guideline as to when to consider CMMRD as differential diagnosis of NF1/Legius syndrome. In addition, counselling and testing strategies are suggested to minimise potential harms. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  clinical genetics; genetic screening/counselling; paediatric oncology

Mesh:

Substances:

Year:  2018        PMID: 30415209     DOI: 10.1136/jmedgenet-2018-105664

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  15 in total

1.  Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism.

Authors:  Eric Legius; Hilde Brems
Journal:  Childs Nerv Syst       Date:  2020-06-29       Impact factor: 1.475

Review 2.  The Challenge of Diagnosing Constitutional Mismatch Repair Deficiency Syndrome in Brain Malignancies from Young Individuals.

Authors:  Cristina Carrato; Carolina Sanz; Ana María Muñoz-Mármol; Ignacio Blanco; Marta Pineda; Jesús Del Valle; Estela Dámaso; Manel Esteller; Eva Musulen
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

3.  Constitutional mismatch repair deficiency-associated brain tumors: report from the European C4CMMRD consortium.

Authors:  Léa Guerrini-Rousseau; Pascale Varlet; Chrystelle Colas; Felipe Andreiuolo; Franck Bourdeaut; Karin Dahan; Christine Devalck; Cécile Faure-Conter; Maurizio Genuardi; Yael Goldberg; Michaela Kuhlen; Salma Moalla; Enrico Opocher; Vanessa Perez-Alonso; Astrid Sehested; Irene Slavc; Sheila Unger; Katharina Wimmer; Jacques Grill; Laurence Brugières
Journal:  Neurooncol Adv       Date:  2019-12-02

4.  A sensitive and scalable microsatellite instability assay to diagnose constitutional mismatch repair deficiency by sequencing of peripheral blood leukocytes.

Authors:  Richard Gallon; Barbara Mühlegger; Sören-Sebastian Wenzel; Harsh Sheth; Christine Hayes; Stefan Aretz; Karin Dahan; William Foulkes; Christian P Kratz; Tim Ripperger; Amedeo A Azizi; Hagit Baris Feldman; Anne-Laure Chong; Ugur Demirsoy; Benoît Florkin; Thomas Imschweiler; Danuta Januszkiewicz-Lewandowska; Stephan Lobitz; Michaela Nathrath; Hans-Jürgen Pander; Vanesa Perez-Alonso; Claudia Perne; Iman Ragab; Thorsten Rosenbaum; Daniel Rueda; Markus G Seidel; Manon Suerink; Julia Taeubner; Stefanie-Yvonne Zimmermann; Johannes Zschocke; Gillian M Borthwick; John Burn; Michael S Jackson; Mauro Santibanez-Koref; Katharina Wimmer
Journal:  Hum Mutat       Date:  2019-03-06       Impact factor: 4.878

Review 5.  Report of the fifth meeting of the European Consortium 'Care for CMMRD' (C4CMMRD), Leiden, The Netherlands, July 6th 2019.

Authors:  M Suerink; K Wimmer; L Brugieres; C Colas; R Gallon; T Ripperger; P R Benusiglio; E M A Bleiker; Z Ghorbanoghli; Y Goldberg; J C H Hardwick; M Kloor; M le Mentec; M Muleris; M Pineda; C Ruiz-Ponte; H F A Vasen
Journal:  Fam Cancer       Date:  2020-07-02       Impact factor: 2.375

6.  Constitutional mismatch repair deficiency in childhood colorectal cancer harboring a de novo variant in the MSH6 gene: a case report.

Authors:  Keinosuke Hizuka; Shin-Ichiro Hagiwara; Takatoshi Maeyama; Hitoshi Honma; Masanobu Kawai; Kiwamu Akagi; Michiko Yasuhara; Naohiro Tomita; Yuri Etani
Journal:  BMC Gastroenterol       Date:  2021-02-10       Impact factor: 3.067

Review 7.  Precision Therapy for Brain Tumors in Hereditary Syndromes.

Authors:  Gerald C Wallace; Madeleine Tjoelker; Kaitlyn Bartley; John W Henson
Journal:  Curr Treat Options Oncol       Date:  2021-07-02

8.  High-sensitivity microsatellite instability assessment for the detection of mismatch repair defects in normal tissue of biallelic germline mismatch repair mutation carriers.

Authors:  Maribel González-Acosta; Fátima Marín; Benjamin Puliafito; Gabriel Capellá; Marta Pineda; Nuria Bonifaci; Anna Fernández; Matilde Navarro; Hector Salvador; Francesc Balaguer; Silvia Iglesias; Angela Velasco; Elia Grau Garces; Victor Moreno; Luis Ignacio Gonzalez-Granado; Pilar Guerra-García; Rosa Ayala; Benoît Florkin; Christian Kratz; Tim Ripperger; Thorsten Rosenbaum; Danuta Januszkiewicz-Lewandowska; Amedeo A Azizi; Iman Ragab; Michaela Nathrath; Hans-Jürgen Pander; Stephan Lobitz; Manon Suerink; Karin Dahan; Thomas Imschweiler; Ugur Demirsoy; Joan Brunet; Conxi Lázaro; Daniel Rueda; Katharina Wimmer
Journal:  J Med Genet       Date:  2019-09-07       Impact factor: 6.318

9.  Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.

Authors:  Peter de Blank; Nan Li; Michael J Fisher; Nicole J Ullrich; Smita Bhatia; Yutaka Yasui; Charles A Sklar; Wendy Leisenring; Rebecca Howell; Kevin Oeffinger; Kristina Hardy; M Fatih Okcu; Todd M Gibson; Leslie L Robison; Gregory T Armstrong; Kevin R Krull
Journal:  Genet Med       Date:  2020-06-23       Impact factor: 8.864

10.  Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation.

Authors:  Eric Legius; Ludwine Messiaen; Pierre Wolkenstein; Patrice Pancza; Susan M Huson; D Gareth Evans; Scott R Plotkin; Robert A Avery; Yemima Berman; Jaishri Blakeley; Dusica Babovic-Vuksanovic; Karin Soares Cunha; Rosalie Ferner; Michael J Fisher; Jan M Friedman; David H Gutmann; Hildegard Kehrer-Sawatzki; Bruce R Korf; Victor-Felix Mautner; Sirkku Peltonen; Katherine A Rauen; Vincent Riccardi; Elizabeth Schorry; Anat Stemmer-Rachamimov; David A Stevenson; Gianluca Tadini; Nicole J Ullrich; David Viskochil; Katharina Wimmer; Kaleb Yohay
Journal:  Genet Med       Date:  2021-05-19       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.